Bladder Cancer

Trial IMvigor011
Cancer Type Bladder Cancer
Hospital(s) Belfast City Hospital
Information

Phase III, double-blind, multicenter, randomized study of atezolizumab (anti-pd-l1 antibody) versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive following cystectomy